Entero Healthcare Solutions Limited
Entero Healthcare Solutions Limited (ENTERO) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Consumer Discretionary›Consumer Services›Retailing›Pharmacy Retail
enterohealthcare.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 993 Cr | 1,034 Cr | 1,097 Cr | 1,301 Cr | 1,359 Cr | 1,339 Cr | 1,404 Cr | 1,571 Cr | 1,707 Cr | 1,910 Cr | 1,940 Cr |
| Operating expenses (approx.) | 964 Cr | 1,005 Cr | 1,067 Cr | 1,258 Cr | 1,309 Cr | 1,290 Cr | 1,354 Cr | 1,509 Cr | 1,639 Cr | 1,824 Cr | 1,844 Cr |
| EBITDA | 29 Cr | 29 Cr | 30 Cr | 42 Cr | 50 Cr | 49 Cr | 50 Cr | 62 Cr | 68 Cr | 86 Cr | 97 Cr |
| OPM % | 2.9% | 2.8% | 2.8% | 3.3% | 3.7% | 3.7% | 3.6% | 4.0% | 4.0% | 4.5% | 5.0% |
| Other income | 2 Cr | 9 Cr | 13 Cr | 11 Cr | 7 Cr | 7 Cr | 6 Cr | 5 Cr | 5 Cr | 4 Cr | 3 Cr |
| Interest | 16 Cr | 17 Cr | 10 Cr | 11 Cr | 10 Cr | 10 Cr | 11 Cr | 12 Cr | 14 Cr | 17 Cr | 21 Cr |
| Depreciation | 6 Cr | 7 Cr | 7 Cr | 7 Cr | 8 Cr | 8 Cr | 9 Cr | 10 Cr | 10 Cr | 15 Cr | 12 Cr |
| Profit before tax | 8 Cr | 14 Cr | 27 Cr | 35 Cr | 39 Cr | 37 Cr | 36 Cr | 45 Cr | 40 Cr | 58 Cr | 67 Cr |
| Tax % | 16.1% | -56.2% | 24.8% | 25.1% | 25.3% | 15.6% | 16.9% | 18.0% | 16.1% | 22.1% | 22.5% |
| Net profit | 7 Cr | 21 Cr | 21 Cr | 26 Cr | 29 Cr | 31 Cr | 30 Cr | 37 Cr | 34 Cr | 45 Cr | 52 Cr |
| EPS (₹) | ₹1.91 | ₹5.73 | ₹4.62 | ₹5.43 | ₹5.85 | ₹5.91 | ₹6.39 | ₹7.26 | ₹6.35 | ₹6.44 | ₹8.77 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
| Sales | 3,922 Cr | 5,096 Cr | 6,591 Cr | Sign in for TTM |
| Operating expenses (approx.) | 3,810 Cr | 4,924 Cr | 6,325 Cr | Sign in for TTM |
| EBITDA | 112 Cr | 172 Cr | 266 Cr | Sign in for TTM |
| OPM % | 2.9% | 3.4% | 4.0% | Sign in for TTM |
| Other income | 14 Cr | 40 Cr | 19 Cr | Sign in for TTM |
| Interest | 66 Cr | 42 Cr | 54 Cr | Sign in for TTM |
| Depreciation | 25 Cr | 31 Cr | 43 Cr | Sign in for TTM |
| Profit before tax | 36 Cr | 139 Cr | 179 Cr | Sign in for TTM |
| Tax % | -11.9% | 22.6% | 18.7% | Sign in for TTM |
| Net profit | 40 Cr | 107 Cr | 146 Cr | Sign in for TTM |
| EPS (₹) | ₹10.81 | ₹21.80 | ₹26.44 | Sign in for TTM |
| Dividend payout % | 0.0% | 0.0% | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity capital | 43 Cr | 44 Cr | 44 Cr |
| Reserves | 1,595 Cr | 1,681 Cr | 1,645 Cr |
| Borrowings | 276 Cr | 299 Cr | 567 Cr |
| Other liabilities | 428 Cr | 633 Cr | 1,281 Cr |
| Total liabilities | 2,345 Cr | 2,703 Cr | 3,600 Cr |
| Fixed assets (net) | 93 Cr | 132 Cr | 103 Cr |
| CWIP | — | 0 Cr | 0 Cr |
| Investments | 0 Cr | 58 Cr | 130 Cr |
| Loans & advances | 0.07 Cr | 0.08 Cr | 0 Cr |
| Inventories | 421 Cr | 660 Cr | 842 Cr |
| Trade receivables | 615 Cr | 830 Cr | 1,212 Cr |
| Cash & bank | 148 Cr | 229 Cr | 147 Cr |
| Other assets | 1,068 Cr | 793 Cr | 1,166 Cr |
| Total assets | 2,345 Cr | 2,703 Cr | 3,600 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from operating activity | -37 Cr | -77 Cr | 96 Cr |
| Cash from investing | -705 Cr | 220 Cr | -303 Cr |
| Cash from financing | 863 Cr | -74 Cr | 124 Cr |
| Net cash flow | 121 Cr | 69 Cr | -83 Cr |
| Free cash flow (OCF − Capex) | -42 Cr | -88 Cr | 29 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| ROCE % | 5.3% | 8.7% | 10.1% |
| ROE % | 2.4% | 5.4% | 6.6% |
| Debtor days | 57 | 59 | 67 |
| Inventory days | 39 | 47 | 46 |
| Days payable | 21 | 28 | 40 |
| Cash conversion cycle | 75 | 78 | 73 |
| Debt / equity | 0.17 | 0.17 | 0.34 |
| Current ratio | 3.34 | 2.46 | 1.58 |
| Net debt / EBITDA | 1.14 | 0.41 | 1.58 |
Compare with peers
Loading peers…